Jacob Househam

Jacob Househam

Auto-generated profile, based on publicly available information

Jacob Househam

Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Nature
Verified
Journal Article
Open access
PDF file
ACAlex J. Cornish
Alex J. Cornish
AGAndreas Gruber
Andreas Gruber
BKBen Kinnersley
Ben Kinnersley
DCDaniel Chubb
Daniel Chubb
AFAnna Frangou
Anna Frangou
Richard HoulstonRichard Houlston
Richard Houlston
Colorectal carcinoma (CRC) is a common cause of mortality1, but a comprehensive description of its genomic landscape is lacking2–9. Here we perform whole-genome sequencing of 2,023 CRC samples from participants in the UK 100,000 Genomes Project, thereby providing a highly detailed somatic mutational landscape of this cancer. Integrated analyses identify more than 250 putative CRC driver genes, many not previously implicated in CRC or other cancers, including several recurrent changes outside the coding genome. We extend the molecular pathways involved in CRC development, define four new common subgroups of microsatellite-stable CRC based on genomic features and show that these groups have independent prognostic associations. We also characterize several rare molecular CRC subgroups, some with potential clinical relevance, including cancers with both microsatellite and chromosomal instability. We demonstrate a spectrum of mutational profiles across the colorectum, which reflect aetiological differences. These include the role of Escherichiacolipks+ colibactin in rectal cancers10 and the importance of the SBS93 signature11–13, which suggests that diet or smoking is a risk factor. Immune-escape driver mutations14 are near-ubiquitous in hypermutant tumours and occur in about half of microsatellite-stable CRCs, often in the form of HLA copy number changes. Many driver mutations are actionable, including those associated with rare subgroups (for example, BRCA1 and IDH1), highlighting the role of whole-genome sequencing in optimizing patient care.

26 October 2022 in Nature
Verified
Journal Article
Open access
PDF file
JHJacob Househam
Jacob Househam
THTimon Heide
Timon Heide
GCGeorge D. Cresswell
George D. Cresswell
ISInmaculada Spiteri
Inmaculada Spiteri
CKChris Kimberley
Chris Kimberley
TGTrevor Graham
Trevor Graham
Genetic and epigenetic variation, together with transcriptional plasticity, contribute to intratumour heterogeneity1. The interplay of these biological processes and their respective contributions to tumour evolution remain unknown. Here we show that intratumour genetic ancestry only infrequently affects gene expression traits and subclonal evolution in colorectal cancer (CRC). Using spatially resolved paired whole-genome and transcriptome sequencing, we find that the majority of intratumour variation in gene expression is not strongly heritable but rather ‘plastic’. Somatic expression quantitative trait loci analysis identified a number of putative genetic controls of expression by cis-acting coding and non-coding mutations, the majority of which were clonal within a tumour, alongside frequent structural alterations. Consistently, computational inference on the spatial patterning of tumour phylogenies finds that a considerable proportion of CRCs did not show evidence of subclonal selection, with only a subset of putative genetic drivers associated with subclone expansions. Spatial intermixing of clones is common, with some tumours growing exponentially and others only at the periphery. Together, our data suggest that most genetic intratumour variation in CRC has no major phenotypic consequence and that transcriptional plasticity is, instead, widespread within a tumour.

26 October 2022 in Nature
Verified
Journal Article
Open access
PDF file
THTimon Heide
Timon Heide
JHJacob Househam
Jacob Househam
GCGeorge D. Cresswell
George D. Cresswell
ISInmaculada Spiteri
Inmaculada Spiteri
CLClaire Lynn
Claire Lynn
ASAndrea Sottoriva
Andrea Sottoriva
Colorectal malignancies are a leading cause of cancer-related death1 and have undergone extensive genomic study2,3. However, DNA mutations alone do not fully explain malignant transformation4–7. Here we investigate the co-evolution of the genome and epigenome of colorectal tumours at single-clone resolution using spatial multi-omic profiling of individual glands. We collected 1,370 samples from 30 primary cancers and 8 concomitant adenomas and generated 1,207 chromatin accessibility profiles, 527 whole genomes and 297 whole transcriptomes. We found positive selection for DNA mutations in chromatin modifier genes and recurrent somatic chromatin accessibility alterations, including in regulatory regions of cancer driver genes that were otherwise devoid of genetic mutations. Genome-wide alterations in accessibility for transcription factor binding involved CTCF, downregulation of interferon and increased accessibility for SOX and HOX transcription factor families, suggesting the involvement of developmental genes during tumourigenesis. Somatic chromatin accessibility alterations were heritable and distinguished adenomas from cancers. Mutational signature analysis showed that the epigenome in turn influences the accumulation of DNA mutations. This study provides a map of genetic and epigenetic tumour heterogeneity, with fundamental implications for understanding colorectal cancer biology.

14 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ELEszter Lakatos
Eszter Lakatos
MWMarc J. Williams
Marc J. Williams
RSRyan O. Schenck
Ryan O. Schenck
WCWilliam C. H. Cross
William C. H. Cross
JHJacob Househam
Jacob Househam
TGTrevor Graham
Trevor Graham

3 January 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
CGCalum Gabbutt
Calum Gabbutt
RSRyan O. Schenck
Ryan O. Schenck
DWDaniel J. Weisenberger
Daniel J. Weisenberger
CKChristopher Kimberley
Christopher Kimberley
ABAlison Berner
Alison Berner
DSDarryl Shibata
Darryl Shibata
Molecular clocks that record cell ancestry mutate too slowly to measure the short-timescale dynamics of cell renewal in adult tissues. Here, we show that fluctuating DNA methylation marks can be used as clocks in cells where ongoing methylation and demethylation cause repeated ‘flip–flops’ between methylated and unmethylated states. We identify endogenous fluctuating CpG (fCpG) sites using standard methylation arrays and develop a mathematical model to quantitatively measure human adult stem cell dynamics from these data. Small intestinal crypts were inferred to contain slightly more stem cells than the colon, with slower stem cell replacement in the small intestine. Germline APC mutation increased the number of replacements per crypt. In blood, we measured rapid expansion of acute leukemia and slower growth of chronic disease. Thus, the patterns of human somatic cell birth and death are measurable with fluctuating methylation clocks (FMCs).

10 September 2025 in Nature
Verified
Journal Article
Open access
PDF file
CGCalum Gabbutt
Calum Gabbutt
MDMartí Duran-Ferrer
Martí Duran-Ferrer
HGHeather E. Grant
Heather E. Grant
DMDiego Mallo
Diego Mallo
FNFerran Nadeu
Ferran Nadeu
TGTrevor Graham
Trevor Graham
Cancer development and response to treatment are evolutionary processes1,2, but characterizing evolutionary dynamics at a clinically meaningful scale has remained challenging3. Here we develop a new methodology called EVOFLUx, based on natural DNA methylation barcodes fluctuating over time4, that quantitatively infers evolutionary dynamics using only a bulk tumour methylation profile as input. We apply EVOFLUx to 1,976 well-characterized lymphoid cancer samples spanning a broad spectrum of diseases and show that initial tumour growth rate, malignancy age and epimutation rates vary by orders of magnitude across disease types. We measure that subclonal selection occurs only infrequently within bulk samples and detect occasional examples of multiple independent primary tumours. Clinically, we observe faster initial tumour growth in more aggressive disease subtypes, and that evolutionary histories are strong independent prognostic factors in two series of chronic lymphocytic leukaemia. Using EVOFLUx for phylogenetic analyses of aggressive Richter-transformed chronic lymphocytic leukaemia samples detected that the seed of the transformed clone existed decades before presentation. Orthogonal verification of EVOFLUx inferences is provided using additional genetic data, including long-read nanopore sequencing, and clinical variables. Collectively, we show how widely available, low-cost bulk DNA methylation data precisely measure cancer evolutionary dynamics, and provides new insights into cancer biology and clinical behaviour.